WISTAR SCIENCE SAVES LIVES ANNUAL REPORT 2014

A YEAR OF COLLABORATION

2014 was a remarkable year for The Wistar Institute. The $102 million building expansion project was completed in September 2014 with the opening of the Robert and Penny Fox Tower. Beyond the brick and mortar, the $35 million capital campaign Building Wistar, Changing the World is nearing completion and will usher in vital new faculty and grow Wistar’s programmatic strengths in cancer research, immunology and infectious disease.

Our scientists and staff exulted in the Fox Tower—a modern and exciting addition to Wistar’s campus and the first new construction in 40 years. Meetings have come out from behind closed doors and into the soaring piazza-like atrium. Scientists have made the open plan, light-filled laboratory spaces thoroughly their home. 89,000 square feet and seven stories later, we are celebrating the moment— and your support—that has allowed us to build for the future and do what we do best: Wistar Science.

2014 was also a series of pivotal moments. The remarkable work our scientists do at “the bench” gained Wistar an “Exceptional” rating from the National Cancer Institute—the highest possible rating a cancer center can earn. At the core of this effort was teamwork and collaboration. Last year witnessed HIV expert Dr. Luis Montaner’s multi-institutional collaboration to begin the largest ever HIV cure-focused clinical trial of its kind—based here in Philadelphia—to drain HIV reservoirs in affected individuals; Dr. Meenhard Herlyn’s progressive melanoma work, bringing together the diverse expertise of Wistar and Penn scientists, garnered a third Special Program of Research Excellence grant awarded to the Institute; and Dr. Louise Showe’s research into lung cancer detection, now in clinical study with industry partners, could make a simple blood test emerge as an important cancer diagnostic tool.

In these pages, we highlight Wistar’s advances in cancer research, strides to develop better vaccines, and progress devoted to tackling HIV/AIDS, along with comprehensive accounts of our activities, administration and governance. 2014 was undeniably seminal, but looking back or looking forward, isn’t that true every year at Wistar?

DARIO C. ALTIERI, M.D. RUSSEL E. KAUFMAN, M.D. President & CEO of The Wistar Institute, President Emeritus of Director of The Wistar Institute Cancer Center, The Wistar Institute and Robert and Penny Fox Distinguished Professor

2014 ANNUAL REPORT 3 We closed 2014 by announcing the evolution of Wistar leadership with Dr. Dario C. Altieri succeeding Dr. Russel E. Kaufman as president & CEO in THE FUTURE March 2015. Dr. Kaufman’s 12 years at Wistar have brought unprecedented scientific accomplishments and accolades, and his legacy has fortified the Institute for years to come. Dr. Altieri is no stranger to Wistar. Since 2010, IS NOW he has been director of Wistar’s National Cancer Institute-designated Cancer Center and Wistar’s first chief scientific officer. Dr. Altieri has galvanized Wistar’s strength in cancer research, recruited world-class investigators and charted a new path for translational medicine that accelerates the progression from basic research to clinical trials with partners in industry and medicine. CONTENTS

6 SCIENTISTS AND CLINICIANS IN TANDEM CREATE BETTER MEDICINE 10 HIV CURE STRATEGY LEADS TO LARGEST CLINICAL TRIAL OF ITS KIND 13 NEW TEST COULD CATCH LUNG CANCER BEFORE IT BECOMES DEADLY 14 HERPES VIRUS REPLICATES BY REARRANGING TELOMERES 16 COLLABORATION LEADS TO PRESTIGIOUS NATIONAL GRANT FOR MELANOMA RESEARCH 17 GRANT HONES IN ON CANCER GENETICS AND CELLULAR SENESCENCE RESEARCH 18 BUILDING A BETTER FLU SHOT 21 REDEFINING THE BUSINESS OF TRANSLATIONAL RESEARCH 22 BORN THIS WAY: THE WORK OF A MILLENNIAL PHILANTHROPIST 24 DELIVERING ON A CAMPAIGN OF PROMISE 26 EVENTS 30 ANNUAL GIVING 34 HERITAGE SOCIETY 35 WISTAR FAMILY GIFTS 36 BOARD OF TRUSTEES This artistic rendering of a human 37 STAFF AND ADMINISTRATION dendritic cell shows how membranes fold back onto the surface of a cell like a set of sheets. These sheet- like structures end up trapping the HIV virus, and then eventually the virus can be transferred to helper T-cells, which contribute to the infection. Photo credit: National Cancer Institute (NCI) SCIENTISTS AND CLINICIANS IN TANDEM CREATE BETTER MEDICINE

Dario C. Altieri, M.D., President & CEO of The Wistar Institute, Director of The Wistar Institute Cancer Center, and Robert and Penny Fox Distinguished Professor

In 2014, the National Cancer Institute (NCI) rated Wistar’s Cancer Center— and its director, Dario C. Altieri, M.D.—as “Exceptional,” the highest possible ranking, and recommended renewal of the Center’s Support Grant with a $14.9 million award over the next five years.

Playing a significant role in securing renewed status as an NCI Cancer Center was Wistar’s commitment to collaboration, both across disciplines and in partnership with other institutions, including the Moulder Center for Drug Discovery at Temple University, the Community College of Philadelphia, and the Christiana Care Health System’s Helen F. Graham Cancer Center & Research Institute in Delaware.

6 THE WISTAR INSTITUTE In its Support Grant renewal, NCI described the Wistar-Graham Center partnership as “extraordinary and innovative.” Wistar, the nation’s first NCI-designated cancer center solely devoted to cancer biology research, and the Helen F. Graham Cancer Center, one of the first NCI-designated community cancer centers, made history when they joined forces in 2011. It was the region’s first and only inter- institutional affiliation between a basic research institution and a community cancer center.

Access to quality patient-derived primary tumor samples from Christiana Care’s Tissue Procurement Center enables Wistar scientists to better study a tumor’s microenvironment and determine how and why cancer grows and spreads. Together, these two centers are working to more quickly “translate” or advance discoveries in cancer medicine from the lab into early phase (Phase I and II) clinical trials with cancer patients at Christiana Care. Given that 80 percent of oncology care is given at community cancer centers like that at Christiana, the pairing is a natural fit. It also fosters opportunities for collaboration, education and funding between researchers and clinicians that would not otherwise be feasible. The end goal: better diagnostic and therapeutic interventions.

Some of the pioneering joint projects in basic biomedical science and translational cancer research underway in 2014 include: LUNG CANCER Louise C. Showe, Ph.D., a professor in Wistar’s Molecular and Cellular Oncogenesis program and director of the Institute’s Genomics Facility, together with Thomas Bauer, M.D., a thoracic surgeon at the Helen F. Graham Cancer Center, are developing a blood test for detecting early stage non-small cell lung cancer. Using blood samples contributed by lung patients through the Tissue Procurement Center, Dr. Showe is working on a more sensitive, less invasive test that uses whole blood, which could easily be drawn at the doctor’s office.

Above, this three-dimensional spheroid was grown from a line of melanoma cells that have a mutation of the NRAS gene. This mutation, which helps the cancer grow and spread, occurs in up to 25 percent of melanoma patients and could be a useful target for new therapies.

2014 ANNUAL REPORT 7 8 THE WISTAR INSTITUTE Scientists analyze tumor samples to identify the genetic drivers of various melanoma subtypes and try to determine why some tumors are resistant to treatment.

MELANOMA Scientists in Wistar’s Melanoma Research Center, the nation’s largest melanoma laboratory outside of the National Institutes of Health, are using tumor samples donated by patients undergoing melanoma surgery at the Helen F. Graham Cancer Center. This invaluable resource provides director Meenhard Herlyn, D.V.M., D.Sc., and his team with a vast range of melanoma subtypes, some previously unavailable, with which they are working to identify genetic drivers and determine why some tumors are resistant to treatment. OVARIAN CANCER AND IMMUNITY José Conejo-Garcia, M.D., Ph.D., professor and program leader for Tumor Microenvironment and Metastasis at Wistar, has teamed up with gynecologic oncologists at Christiana Care on ovarian cancer research. Dr. Conejo-Garcia uses tumor samples from the Tissue Procurement Center to verify that previous animal model findings reflect what actually happens in human disease.

Dr. Conejo-Garcia wants to learn more about how ovarian cancer acts on the body’s natural defenses to enable tumor growth. His laboratory is attempting to identify tumor surface markers that could become targets for early detection—a critical need, considering there is currently no effective screening test for ovarian cancer. His lab is also working to culture ovarian tumor cell lines to study tumor progression and to test new drugs. Dr. Conejo-Garcia and his team co-authored two papers on this work with gynecologic specialists at Christiana Care.

Christiana’s Tissue Procurement Center is also supplying custom-prepared, protocol-driven samples of peripheral blood and cancer tumors to Dmitry Gabrilovich, M.D., Ph.D., and investigators in his Translational Tumor Immunology program. They are looking at various types of myeloid cell defects and how cancer impacts their role in the body’s immune response. Some of their proposed therapeutic strategies to overcome these actions are being tested in clinical trials.

Above, this three-dimensional image of a melanoma cell was obtained using a special type of electron microscope that is able to render cells that have a very small resolution. Photo credit: NCI

2014 ANNUAL REPORT 9 HIV CURE STRATEGY LEADS TO LARGEST CLINICAL TRIAL OF ITS KIND

Luis J. Montaner, D.V.M., M.Sc., D. Phil., Herbert Kean, M.D., Family Professor; Professor and Director, HIV-1 Immunopathogenesis Laboratory; Member, Tumor Microenvironment and Metastasis Program

10 THE WISTAR INSTITUTE “With this funding, Philadelphia will conduct the largest randomized trial anywhere focused on testing an easily accessible strategy to advance an HIV cure.” Dr. Luis J. Montaner

When patients with the human immunodeficiency virus (HIV) are treated successfully, a small amount of the virus can linger in cells, ready to accumulate and multiply rapidly, thus making the disease impossible to cure. Now, research that originated at The Wistar Institute aims to deplete the HIV virus from these “viral reservoirs.” At a time when many HIV cure strategies are still being tested in small pilot studies, Wistar will move forward with the first National Institutes of Health (NIH)-funded randomized trial on a strategy directed at a cure.

Luis J. Montaner, D.V.M., D.Phil., received a four-year, $6.2 million grant from the National Institute of Allergy and Infectious Disease of the NIH to test this new strategy. Dr. Montaner conducted a pilot trial showing that interferon-alpha, a protein that modulates the immune system, can reduce the persistent amount of HIV-1 residing in people with HIV/AIDS who currently receive treatment with antiretroviral therapy.

Current therapies keep the virus at bay, but never reduce the amount of the virus that remains in the patient.

“An HIV cure will require going beyond current therapies, and our strategy has shown itself capable of doing that,” said Dr. Montaner. “With this funding, Philadelphia will conduct the largest randomized trial anywhere focused on testing an easily accessible strategy to advance an HIV cure.”

Dr. Montaner is collaborating with multiple clinics across Philadelphia under the supervision of Jay R. Kostman, M.D., a clinical professor of medicine in the Division of Infectious Diseases at the Perelman School of Medicine at the University of Pennsylvania. They will supervise a randomized trial of 54 patients to conclusively determine the effectiveness of this strategy. The team is comprised of investigators and clinicians based at The Wistar Institute, the University of Pennsylvania, the University of California, and Philadelphia FIGHT.

The $6.2 million grant will go toward clinical and administrative expenses of the trial as well as the laboratory follow-up allowing researchers to quantify their results. Laboratory results look to determine how quickly HIV-1 replicates following interruption of antiretroviral therapy, the amount of HIV DNA integrated into host T cells, and the amount of virus hiding in reservoirs. Dr. Montaner’s lab will also examine the mechanics of how the immune system responds to the immunotherapy.

Above, HIV attacks and destroys the infection-fighting T-cells, which are crucial to the immune system’s ability to fight off invading viruses and germs. Once in the body, the virus can replicate over and over again until the infected cells outnumber the healthy T-cells. Photo credit: National Institute of Allergy and Infectious Diseases (NIAID)

2014 ANNUAL REPORT 11 Louise C. Showe, Ph.D., Professor, Molecular and Cellular Oncogenesis Program; Associate Director, Center for Systems and Computational Biology; Scientific Director, Genomics Facility; and Scientific Director, Bioinformatics Facility

12 THE WISTAR INSTITUTE NEW TEST COULD CATCH LUNG CANCER BEFORE IT BECOMES DEADLY

A new, easy-to-use blood test developed at The Wistar Institute could detect lung cancer before it spreads. A clinical trial to gauge the test’s effectiveness is underway, and its organizers report it has reached its goal of 600 volunteer participants who are considered at high-risk for developing lung cancer.

This tool was developed at Wistar by Louise Showe, Ph.D. In a series of previous studies, Dr. Showe demonstrated that lung cancer could be detected before symptoms appear by taking a snapshot of gene activity in blood-borne immune cells.

The need for early detection is important in all types of cancer, but this is especially true in lung cancer. The rate of survival for patients with lung cancer drops dramatically the later it is detected. Patients diagnosed with non-small cell lung cancer at stage IA, or very early stage lung cancer, have a 49 percent chance of survival five years after diagnosis, according to the American Cancer Society. However, patients who are diagnosed with stage IV disease, which means the cancer has metastasized and spread to other organs, have only a 1 percent chance of achieving five-year survival.

By October 2014, more than 600 blood samples from patients considered at high-risk for developing lung cancer had been collected at six clinical sites, including the Helen F. Graham Cancer Center in Delaware and Temple University Hospital in Philadelphia. All sites met or exceeded their collection goals. Wistar scientists are currently looking at this data and analyzing gene expression signatures, or the molecular “fingerprints” that disclose the presence of lung cancer.

“The need for more sensitive, cost-effective, and less invasive methods to detect and monitor cancer in humans, particularly in lung cancer, is not going away,” said Dr. Showe. “We look forward to expanding our studies through this collaboration in order to detect and monitor this devastating cancer.” Lung cancer lesion There are two main types of lung cancer. Most are non-small-cell lung cancer, shown here at right. Small-cell lung cancer is more aggressive and likely to spread to other parts of the body early on. Photo credit: James Heilman, M.D.

2014 ANNUAL REPORT 13 HERPES VIRUS REPLICATES BY REARRANGING TELOMERES

Paul M. Lieberman, Ph.D., Hilary Koprowski, M.D., Endowed Professor; Professor and Program Leader, Gene Expression and Regulation Program; Director, Center for Chemical Biology and Translational Medicine; and Scientific Director, Protein Expression and Libraries Facility

14 THE WISTAR INSTITUTE The herpes simplex virus 1 (HSV-1), shown in green, is able to rearrange telomeres, the small protective ends of DNA that protect our chromosomes, shown in red. This viral-manipulation might explain why the herpes virus is able to replicate so effectively in older cells where telomeres are shorter due to aging.

Herpes simplex virus 1 (HSV-1) is the aggressive virus closely associated with cold sores, which can lead to more severe disease. The virus can rearrange the crucial protective ends of our chromosomes called telomeres. These findings show how a virus like herpes is able to multiply while also revealing more about the role of telomeres, which prevent our chromosomes from breaking, and their ability to stop viruses in their tracks.

The results were published by the journal Cell Reports.

Paul Lieberman, Ph.D., lead author of this study, said that telomeres play a very important part in the lifespan of a cell.

“We wanted to know whether they also play a role in viral replication or protection from viruses, and our findings suggest—at least in the case of the herpes simplex virus—that this may indeed be the case,” Dr. Lieberman said.

Telomeres keep chromosomes from unwinding and breaking (much like the clear tips on the end of shoelaces that prevent fraying). This is crucial because chromosomes hold all of our vital genetic information.

This lab studied HSV-1 because it’s an aggressive virus able to replicate in the cell nucleus where our chromosomes and telomeres are found. Commonly known for causing cold sores, HSV-1 can also lead to more serious diseases like blindness and encephalitis. About 65 percent of Americans show signs of past infection; and there is no vaccine for the virus and only a small handful of effective treatments.

The study by Dr. Lieberman and his colleagues found that the virus can degrade a telomere protein called TPP1, which is part of a complex of proteins furnishing protection to telomeres. When the TPP1 protein is shut down, HSV-1 uses a protein called ICP8 to promote viral genomic replication.

“This study expands our knowledge of telomeres further in two very important ways,” Dr. Lieberman said. “First, it gives us an indication that some viruses are able to manipulate telomeres specifically in order to replicate. Second, it appears that proteins like TPP1 provide very specific protective functions. These findings allow us to ask additional questions and better understand just how telomeres may protect cells from viral infection.”

Dr. Lieberman’s research could eventually bridge the gap to clinical application.

“Paul’s work is not only groundbreaking but tremendously promising,” said Dr. Russel E. Kaufman, president emeritus of The Wistar Institute. “Fundamental research efforts lead to discoveries and are always where we have the greatest potential for life-saving treatments.”

2014 ANNUAL REPORT 15 COLLABORATION LEADS TO PRESTIGIOUS NATIONAL GRANT FOR MELANOMA RESEARCH

In September 2014, Wistar announced the receipt of a $12.1 million Special Program of Research Excellence (SPORE) grant to develop new therapies for melanoma—the deadliest form of skin cancer and the fifth deadliest form of cancer, overall. This prestigious National Cancer Institute collaborative grant brings together researchers at Wistar and the University of Pennsylvania to translate fundamental laboratory discoveries into new therapeutics that will benefit patients with melanoma and other skin cancers. Wistar is the first basic research, NCI- designated Cancer Center to be awarded a SPORE grant.

Meenhard Herlyn, D.V.M., D.Sc., Caspar Wistar Meenhard Herlyn, D.V.M., D.Sc., principal Professor in Melanoma Research and Director, The Wistar Institute Melanoma Research Center investigator on the grant, will lead this collaborative effort with cutting-edge research on new melanoma therapies, strategies and diagnostics— the result of over 30 years of teamwork that has evolved between Wistar and the University of Pennsylvania. Further, the SPORE grant will be a model to establish an organizational structure on campus for future research on melanoma and other skin cancers.

Specifically, the grant will fund four melanoma research projects that explore new therapies and Melanoma cells are grown as cancer genetics: targeted combination therapy, three-dimensional spheroids autophagy modulation, genetic marker research embedded in collagen to mimic related to certain therapies, and engineered T cell the tumor microenvironment (cells, molecules and blood therapy. It also supports three “cores” of work to vessels that surround and feed further support the team’s efforts: an administrative a tumor) and can then be core to support collaboration between researchers, studied. The green fluorescence indicates live cells and the red a biospecimen and pathology core to provide fluorescence indicates dead cells. researchers with high-quality tumor samples, and a biostatistics core to help analyze and disseminate research on experiments and clinical studies.

16 THE WISTAR INSTITUTE GRANT HONES IN ON CANCER GENETICS AND CELLULAR SENESCENCE RESEARCH

Building on a deeply-rooted commitment to advance our understanding of cancer genetics, Wistar was awarded a $100,000 grant from The W.W. Smith Charitable Trust in December 2014 for research on cellular senescence—a state of stable cell growth arrest—that suppresses the development of human cancers. The W.W. Smith Charitable Trust is a private foundation that provides funding to support basic medical research primarily in the areas of heart disease, cancer and AIDS.

Led by Ken-ichi Noma, Ph.D., the project—titled “Regulation of Cellular Senescence Through 3-D Genome Organization”—will investigate how Ken-ichi Noma, Ph.D., Associate Professor, Gene Expression and Regulation Program alterations in the 3-D genome architecture affect gene expression and drive cellular senescence.

Throughout his career, Dr. Noma has been hard at work to better understand the molecular underpinnings of human cancers, especially cancers that result from the disorganization of the cell nucleus. He uses a variety of investigative mechanisms to regulate the genome structure and better understand its biological significance. At a time when cancer is on the rise, the grant will allow for a more focused look, using the latest technical advances, into cellular senescence and complex As we age, our cells eventually 3-D genome structures. become senescent, meaning that they lose their ability to grow and divide. Dr. Noma has discovered that the chromo- somes found in these senescent cells are organized differently than in normal, healthy cells. If we could turn cancer cells into senescent cells, they would stop growing, and this might help slow down the progression of the tumor. Knowing this could allow researchers to either reverse senescence in healthy cells or increase senescence in cancerous cells.

2014 ANNUAL REPORT 17 Jan Erikson, Ph.D., Professor, Vaccine Center

Every fall, Americans dutifully get flu shots and anticipate the vaccination will protect them against that season’s virus strain (or strains). Some BUILDING years the vaccines are better than others, but the risk of serious illness from influenza remains a threat—the seasonal influenza virus kills 36,000 A BETTER Americans annually and is the nation’s eighth leading cause of death. Two investigators in Wistar’s Vaccine Center are studying the biology of influenza infection to make annual flu shots FLU SHOT more effective, as well as investigating ways at reducing secondary infection. Both scientists published papers in 2014 on recent flu-related discoveries.

If a secondary respiratory infection like bacterial pneumonia (pneumococcus) develops following a bout with the flu, there’s a greater risk of becoming sicker or even dying. Professor Jan Erikson, Ph.D., discovered that if the order of infection is reversed—if the flu infects after

18 THE WISTAR INSTITUTE Scott E. Hensley, Ph.D., Assistant Professor, Vaccine Center

pneumococcus is already present—it may be possible to actually protect patients against severe flu- related illness. Her research was recently published in the journal Virology.

Scientists in Dr. Erikson’s lab demonstrated that if the respiratory tract of mice is colonized with pneumococcus prior to exposure to influenza, the virus is significantly less likely to be severe or progress to a secondary infection. This discovery can help researchers advance potential strategies to prevent secondary bacterial infections and improve overall outcomes.

Another Wistar study examined why during the 2013-2014 flu season middle-aged adults got sicker than typically more vulnerable populations of children and the elderly. Led by Scott E. Hensley, Ph.D., the team of investigators identified a mutation in recent H1N1 influenza strains allowing viruses to avoid immune responses present in nearly half of adults born between 1964 and 1979, leading to increased disease incidence.

His team’s data suggests that previous influenza exposure in the 1970s and 1980s influenced how middle-aged people responded to the current H1N1 vaccine. Published in Proceedings of the National Academy of Sciences, the findings suggest the need to update the seasonal flu vaccine each year with new viral strains to help build broader immunity.

Both Drs. Erikson’s and Hensley’s discoveries inform the Vaccine Center’s ongoing work in pursuit of a single, universal seasonal influenza vaccine to ultimately replace yearly injections, and the uncertainty that accompanies them.

2014 ANNUAL REPORT 19 The Business Development team consists of (clockwise from left) Heather A. Steinman, Ph.D., M.B.A., Vice President for Business Development and Executive Director of Technology Transfer, Christopher Harold Croft, Contracts and Intellectual Property Specialist, Kathy Day, Administrative Coordinator, and Dustin Shilling, Ph.D., Senior Associate of Licensing and Business Development.

20 THE WISTAR INSTITUTE REDEFINING THE BUSINESS OF TRANSLATIONAL RESEARCH

The Wistar Institute is known for its nimble approach to research and support for unfettered innovation. So too, is Heather A. Steinman, Ph.D., M.B.A., Wistar’s dynamic new vice president for Business Development and executive director of Technology Transfer. Steinman is revitalizing Wistar’s technology commercialization activities, tearing down silos and removing any barriers that might stand in the way of the transformative, life-saving possibilities of Wistar Science.

Steinman’s creative vision is to unite scientists with strategic partners in the life sciences start-up community and pharmaceutical industry with the goal of converting Wistar’s growing repertoire of targeted cancer treatments, diagnostics, vaccines, and discovery platforms into biomedical breakthroughs. This catalytic approach to removing the risks from early stage science ensures a higher likelihood for success and accelerates the opportunity for innovative projects to move forward.

To help translate Wistar’s special brand of biomedical research into life-saving solutions, while also generating income to support further research and education, Steinman relies on her team of experts: Dustin Shilling, Ph.D., senior associate for licensing and business development, Christopher Harold Croft, contracts and intellectual property specialist, and Kathy Day, administrative coordinator.

“We can do business in a proactive, accelerated way at Wistar—we have no red tape, which enables us to harness our efforts toward the end goal, not the bureaucratic process,” said Steinman. “Wistar’s stellar science is a powerful portfolio for pre-clinical target discoveries. What an exciting time to be part of Wistar and to have this agile dynamic team that can step in early to leverage our assets and nurture valuable industry relationships for our researchers and the Institute.”

For Steinman, the key to success is about the connections. In business, it has to be personal.

2014 ANNUAL REPORT 21 At center stands Lynsie Solomon, Wistar Ambassador Founder and Chair, surrounded by Wistar Ambassadors at the Sips, Schmooze & Science event at the Capital Grille.

BORN THIS WAY: THE WORK OF A MILLENNIAL PHILANTHROPIST

Wistar Institute Leadership Council member and Wistar Ambassador founder and chair Lynsie Solomon has arrived early for the Sips, Schmooze & Science event, and steps into Wistar’s new atrium with a close-knit ring of supporters including her mom, friends and Wistar Ambassadors. Each one carries a bag brimming with raffle items: spa day lotions and potions, ties and scarves, bottles of top shelf liquor, and gift certificates as well as the necessities for gift wrapping: cellophane, wicker baskets, ribbon, and scissors. Two hours later, seven high-end raffle baskets combined with ticket sales raise more than $4,000. It’s just another day after her day at the office; a night of do-gooding, cementing ties and making an impact.

Lynsie is committed to being part of something greater than herself. Though she has a full-time job, she finds time to be a young member of numerous esteemed arts and science organizations, including a committee member and 2016 vice chair of the Young Friends of the Academy of Music, 2015 co- chair of the Ladies Committee of the Union League, a member of the Sidney Kimmel Cancer Center Next Generation, and a sponsorship chair board member for Donors Are Heroes.

“When I was growing up, my parents were very involved in charitable work and they taught me to give—both money and time,” Lynsie said. “My husband Evan’s mentors have exposed us to events with a cause and, through like-minded people, we have learned about the many social issues and needs in Philadelphia.”

Happening upon a Wistar event through a friend, Lynsie wanted to get to know Wistar at a deeper level, and returned to meet and tour the Wistar campus with Dr. Russel E. Kaufman, president emeritus.

“I was empowered when I met Dr. Kaufman—how can anyone not get involved with Wistar when they meet him?” said Lynsie. “I learned what a scientific powerhouse Wistar is in cancer research and

22 THE WISTAR INSTITUTE vaccine work, and concluded that Wistar scientists should never have to fear interrupting or stopping their research. I simply asked how could I help.”

The mantra “Wistar Science Saves Lives” was a clear, strong mission statement that attracted Lynsie to the Institute.

“I want to be a part of an organization making huge strides—and, basically, saving the world,” Lynsie explained. “Wistar is doing that on all levels. The scientists working ‘at the bench’ are the best of the best in understanding the basic mechanisms behind melanoma, breast, ovarian, and prostate cancers. And now there’s so much progress in translating their discoveries to therapies. Wistar’s mission makes my head spin with excitement.”

Lynsie and her husband, Evan Solomon, came aboard as Wistar Leadership Council members in 2013. At meetings, they quickly realized that they were the youngest people in the group.

“I had a great mentor in (former Leadership Council chair) Ed Ryan and he motivated me to get more involved,” Lynsie explained. “I felt like it was a great opportunity to engage young people in Wistar’s work. Then I worked with Elyse Hoffmann, Wistar donor relations and special events director, on our first event and that forged a strong relationship.”

Lynsie and Elyse combine their skill sets and expertise to create events that are cementing relationships with ambitious, new philanthropists in and around Philadelphia. These next generation supporters bring a fresh perspective to Wistar and are committed to investing their time, money and energy.

“I would like to see twice as many Ambassadors and be able to raise a substantial donation to give in 2015,” Lynsie stated. “The Ambassadors aren’t here to enjoy just another happy hour. They are here for the long haul and are engaged and passionate about the work Wistar does.”

Ambassador founder and chair Ambassador member Andrew Peshek and Ambassador Lynsie Solomon and Evan Solomon Gabriela Guaracao and member Leah Reinhard Matthew Fontana

MARCH 19, 2014, AT ROSA BLANCA IN PHILADELPHIA COCKTAILS AND The Wistar Ambassadors are a group of young residents in the Philadelphia region 40 years old and under who want to learn more about Wistar’s bold BITES WITH new advances in cancer research and find new ways of raising local and national awareness of these efforts.

THE WISTAR At this inaugural party, guests spent the evening in an exclusive and intimate setting as Russel E. Kaufman, M.D., president emeritus of The Wistar Institute, AMBASSADORS was on hand to discuss the important science taking place at Wistar and answer questions from this young group of Philadelphians.

All photos courtesy of HughE Dillon.

2014 ANNUAL REPORT 23 DELIVERING ON A CAMPAIGN OF PROMISE

In 2010, Wistar announced a five-year, $35 million capital campaign—Building Wistar, Changing the World—designed to sow the seeds for its first major building project since 1976 and secure the Institute’s future at the forefront of cancer research, genetics and vaccine development. The opening of the much-anticipated Robert and Penny Fox Tower in September 2014 heralded a new era of team science at Wistar, with enhanced cross-disciplinary collaboration and new partners in medicine and industry that will accelerate basic biomedical discoveries into life-saving inventions. Erecting the cutting-edge $100 million research facility and equipping scientists with the latest technologies were only part of the first phase of the campaign’s objective. Funds raised will complete remaining aspects of the expansion and support a $10 million initiative to recruit world-class scientists who will complement the strengths of Wistar’s faculty while broadening capabilities in pioneering new areas of research. Thanks to the leadership of Robert and Penny Fox and the generous support of the board of trustees, the capital campaign steering committee, and numerous individuals, the campaign has raised more than $30.5 million—an investment in Wistar’s paramount mission to save lives as it heads into the final year of the campaign.

“Caspar” hangs at the main entrance of the Robert and Penny Fox Tower and is named after Caspar Wistar, M.D. Symbolic of a DNA helix, its smooth center curve anchors protein tendrils and Wisteria— named by the botanist Thomas Nuttall after his friend Dr. Wistar. Made of painted brass mesh and copper, the kinetic sculpture makes a full rotation every six minutes and was created by visual artists Kate Kaman and Joel Erland. 24 THE WISTAR INSTITUTE At the top of the Fox Tower’s grand stairway is the Atrium, the principal point for circulation between the historic and new buildings. This light-filled, inspiring gathering space welcomes visitors and students alongside scientists and distinguished guests to an open and inviting plaza that enhances Wistar’s mission of discovery, collaboration and community.

The stunning visual focus of the Atrium is the Feature Wall, a series of 15 high-definition TV screens that presents dynamic images and visual programming to highlight the Institute’s science, scientists and stories as well as educate and inspire an appreciation of science and its immense impact.

2014 ANNUAL REPORT 25 EVENTS

THE WISTAR INSTITUTE’S MELANOMA AWARENESS DAY WITH THE PHILLIES Presented by Citizens Bank and Independence Blue Cross

Wistar’s Melanoma Awareness Day at Citizens Bank Park was stellar. Dr. Russel E. Kaufman, president emeritus, threw out the ceremonial first pitch in front of a crowd of more than 30,000 baseball fans, and the busy night proved ideal for Wistar to spread the message of melanoma prevention. Also, through the Phillies Charities, Inc., 50/50 Drawing, Wistar received $5,378.75—a quarter of the proceeds from the 1 2 drawing’s raffle sales collected on game night. 5.13.2014

3 4

6 7

1. Daniel K. Fitzpatrick, Citizens Bank President and CEO of PA/NJ/ DE/NY; and Russel E. Kaufman, M.D., Wistar president emeritus 2. Russel E. Kaufman, M.D., throws out the first pitch 3. Wistar scientists and the Phillies Phanatic take a bow after dancing on the dugout 4. On the Jumbotron, Phillies Hall-of-Famer and stage-3 melanoma survivor Mike Schmidt spread the message of sun safety to a packed ballpark 5. Three young baseball fans show “they all have skin in this game” with Wistar wrist bands and sunglasses 6. Wistar volunteer and graduate student Amanpreet Kaur hands out sunblock and sun-sensitive wrist bands to the crowds at the ballpark entrance 5 7. Wistar friends and scientists enjoy a night out at the ball park

26 THE WISTAR INSTITUTE EVENTS

19TH ANNUAL ALBERT R. TAXIN GOLF & BRIDGE CLASSIC A vivid green golf course seemingly endless under breezy, clear blue skies contributed to an outstanding day of golf and bridge at the Green Valley Country Club in Lafayette Hill, Pa. The Albert R. Taxin Golf & Bridge Classic, established to honor the memory and legacy of Albert R. Taxin, raised record-setting proceeds to support the vital work taking place in the Albert R. Taxin Brain Tumor Research Center at The Wistar Institute. 1 5.19.2014

2 3

1. A perfect sunny day was par for the course for Robert A. Fox and Coach Dick Vermeil. 5 2. Event co-chair Garry Maddox and John Binswanger pause for a photo during the reception 3. Robert A. Fox, Alan Miller, and president emeritus Dr. Russel E. Kaufman 4. Wistar volunteers handling the check-in table: Kate O’Neill, Tina Ciarrocchi, Alan Spooner, Rita Manfre, Mary Fenkel and Claire Rose 5. Foursome golfers Peter Brandow, Karen Schulze, Laura and Mark Lenet 6. Team golfers Bruce Downs, Sandy and Louis Rousso and Anthony Dent 7. Marybeth Driscoll, Ralph Wellington, and Mary Bak took a break from some memorable shots on par

6

4 7

2014 ANNUAL REPORT 27 EVENTS

PRESIDENT’S AWARD LUNCHEON HONORING ALLAN H. (BUD) SELIG Allan (Bud) Selig, the commissioner emeritus of Major League Baseball, was the 2014 recipient of The Wistar President’s Award. The President’s Award recognizes a public figure who has been personally touched by 1 cancer, and who advocates for improvements in cancer education and research. Selig is an outspoken melanoma cancer survivor who uses the ballpark as his platform to raise awareness about melanoma, the deadliest form of skin cancer.

5.28.2014 2

3 4 5

1. Dr. Jerry Herman, Bud Selig, Abe Morris, and Dr. Russel E. Kaufman, president emeritus 2. Wistar’s, melanoma team with the MLB Comissioner: Drs. Meenhard Herlyn, Ashi Weeraratna, Maureen Murphy, and Jessie Villanueva 3. Bud Selig and Joe Grusemeyer 4. Wistar Board Trustee Chair Helen Pudlin, Bud Selig, and Board member Ronald Caplan 5. Sandra and Michael Widlitz, Kate O’Neill, director and president of the Noreen O’Neill Foundation for Melanoma Research, and Dr. Meenhard Herlyn, Director of Wistar’s Melanoma Research Center 6. Guests at the President’s Award Luncheon in the Diamond Club at Citizens Bank Park

6

28 THE WISTAR INSTITUTE EVENTS

UNVEILING OUR NEW TOWER: THE ROBERT & PENNY FOX TOWER GALA There could not have been a more distinctive and appropriate celebration of the Robert and Penny Fox Tower than the red carpet affair that took place on September 12, 2014. Wistar’s highly- anticipated gala kicked off with a ribbon- cutting ceremony by president emeritus Dr. Russel E. Kaufman—with General Isaac J. Wistar’s ceremonial Civil War sword in hand—officially slicing the ribbon and signaling the start of a brilliant evening of 1 entertainment. Guests were led up to the 5th and 6th floor laboratories, where they sipped cocktails out of test tubes and talked about the future of Wistar science. They enjoyed a magnificent dinner, served by lab coat-clad servers, on the main floor of the new research tower. BalletX performed, an oxygen bar offered aromatherapy scents and conversations continued into the night. 2 3 9.12.2014

4 5

1. Robert and Penny Fox are presented with a model of the Tower 2. Wistar Leadership Council member James Li with wife Audrey 3. State Senator Anthony Williams, Robert A. Fox, Dr. Russel E. Kaufman, Penny Fox, and State 6 Rep. James Roebuck gather for the ceremony 4. Abe Morris, Art Pappas, Dr. Jerry Herman, and Dr. Dario C. Altieri enjoy cocktails in a lab of the Fox Tower 5. Rick Horowitz, Joseph Kestenbaum, Ruth Horowitz, Max and Elyse Berger, and Sharon Kestenbaum together in the new atrium of the Fox Tower 6. Wistar’s glamorous scientists 7. BalletX ballerinas surprised guests with a “pop up” performance during dinner 8. A view of the Atrium from above

7 8

2014 ANNUAL REPORT 29 ANNUAL GIVING

THANK YOU

The Wistar Institute wishes to thank all of our donors who generously invest in our mission to contribute to the prevention and cure of cancer and related diseases. Each of these individuals, corporations, and foundations listed below made a gift of $500 or more between January 1 and December 31, 2014.

Mr. and Mrs. Max M. Berger BNY Mellon Wealth Management ISAAC WISTAR SOCIETY $500,000+ Mr. and Mrs. Douglas S. Briggs Anonymous Mrs. June H. Chern Innisfree Foundation Citizens Bank Wellcome Trust Mr. and Mrs. Harold M. Davis W. W. Smith Charitable Trust John and Rosemary Diederich Brian and Elizabeth Dovey Mr. and Mrs. Joseph J. Fenkel Ms. Debra Fox CENTENNIAL SOCIETY $100,000+ Mr. Kenneth A. Fox Ms. Nancy Fox and Mr. Jon Edwards Ira Brind and Stacey Spector Dr. L. Patrick Gage and Ms. Irina Wilson-Gage The Horace W. Goldsmith Foundation Stan & Arlene Ginsburg Family Foundation The G. Harold & Leila Y. Mathers Charitable Foundation The Anne M. and Philip H. Glatfelter, III Family Foundation Melanoma Research Alliance Mr. and Mrs. Bruce A. Goodman PTS Foundation Reuben and Mollie Gordon Foundation Dr. Karl F. Rugart, Jr.* Mr. and Mrs. Donald C. Graham Sibley Memorial Hospital Gray Charitable Trust Mrs. Frances Tobin Marcy Gringlas and Joel Greenberg The Hassel Foundation Hess Foundation, Inc. Ruth and Richard Horowitz PATRONS $50,000+ Independence Blue Cross Janssen Biotech Services, Inc. Alliance for Cancer Gene Therapy W. M. Keck Foundation American Cancer Society Mr. Martin P. Krasner Nancy and Robert S. Blank Mr. Perry Lerner and Ms. Lenore Steiner Ellen and Ronald Caplan LF Driscoll Connelly Foundation Mr. Ira M. Lubert The Doctors Cancer Foundation Susan and Graham McDonald Jane and Joseph Goldblum Mr. and Mrs. Alan B. Miller Herbert Kean, M.D. and The Honorable Joyce Kean Morphotek, Inc. Mr.* and Mrs. Thomas F. Lafferty Mr. and Mrs. Abraham L. Morris Mr.* and Mrs. Herbert Lotman The Warren V. Musser Foundation Martha and I. Wistar Morris III Albert Ominsky, Esquire and Paula Dresnin Noreen O’Neill Foundation for Melanoma Research Pennsylvania Breast Cancer Coalition The Philadelphia Foundation Philadelphia Phillies Seymour S. Preston III and Jean E.H. Preston PNC Mr. and Mrs. Gerald B. Rorer Helen and David Pudlin RAF Industries Mr. and Mrs. Robert H. Rock Martha W. Rogers Charitable Trust GUARANTORS $10,000+ Mr. and Mrs. Lester Rosenfeld Mr. and Mrs. Ronald Rubin Robert and Marta Adelson Mr. Seymore Rubin Mary Rhoads Alexander Paul and Sharon Schmitt Mr. David Anderson and Mrs. Elizabeth McKee Anderson Schnader Harrison Segal & Lewis LLP Ballinger Architecture & Engineering William A. Slaughter, Esquire Mrs. Ian J. Berg Doris Taxin and Jack Stievelman

30 THE WISTAR INSTITUTE Mr. James D. Troyer and Ms. Kathleen Callan Ms. Agatha Koprowski Mr. and Mrs. Richard A. Vermeil Mr. and Mrs. Seymour G. Mandell Mr. and Mrs. David V. Wachs Jennifer Mendel and Fred Fox Samuel Waxman Cancer Research Foundation E. K. Pomerantz Miller Mr. and Mrs. Bryan S. Weingarten National Catholic Community Foundation Dan Wheeler and Amy Fox NAXION Mr. and Mrs. Timothy Pesce E. Prem Reddy, Ph.D. Anne Rhoads and Noureddine Melikechi PRESIDENT’S SOCIETY INSURERS $5,000+ Mr. and Mrs. Ernest Scheller, Jr. Mr. and Mrs. Fred Shabel Mr. and Mrs. William A. Albert Elaine Shapiro American Heart Association Ed Sickles Family The Arthur Jackson Company Lynsie and Evan Solomon The Barra Foundation Greg and Alex Stanbach Mr. and Mrs. John K. Binswanger Universal Health Services, Inc. Ms. Stacy Chern and Mr. Ty Wu University of Colorado School of Medicine Ellen and Winston Churchill Veritable, LP Colonial Consulting, LLC Mr. and Mrs. Laurence N. Weiss Sandy and Stephen Cozen Willis of Pennsylvania, Inc. Mrs. Margaret F. Cristofalo Drexel University Eli Lilly and Company Mr. and Mrs. Mark Fishman Penny and Robert Fox PRESIDENT’S SOCIETY FELLOWS $1,000+ Mr. and Mrs. Steven C. Graham Mr. Michael Ackerman Dr. and Mrs. Peter Gross Mr. and Mrs. Benjamin Alexander Estate of Arthur Hermann Mr. Scott Barsky The Honickman Family Joseph Boardman, Esq. Dr. and Mrs. Russel E. Kaufman Dani P. Bolognesi, Ph.D. Mr. and Mrs. Joseph Kestenbaum Mr. and Mrs. Martin Brait Mr. and Mrs. H. Lewis Klein Mrs. Barbara Cantor Dr. Christopher Koprowski Dr. Catherine Chern and Mr. John Auyeung Jane and Leonard Korman David and Rhonda Cohen Susanna Lachs and Dean Adler Mr. and Mrs. Matt Cohen Garry Maddox, A. Pomerantz & Co. Mr. and Mrs. Norman Cohn Henry S. Miller, Jr. and J. Kenneth Nimblett Comcast-Spectacor Maida R. Milone Debbie and I. Michael Coslov Mr. David P. Montgomery Carlo M. Croce, M.D. Oxford Area Foundation Joanne and Donnie Davidow Mr. and Mrs. Arthur Pappas Joan M. Farkas and Bruce T. Downs Dr. and Mrs. Stanley A. Plotkin Mr. and Mrs. Joseph M. Field The Edward and Elsa Rhoads Trust First Federal of Bucks County William and Inés Rhoads Fisher Scientific Mr. Brett Rhode Mrs. Annabelle Fishman The Scholler Foundation Mr. and Mrs. Richard J. Fox Judith Soltz and Richard Belas Mrs. Linda Frankel Susan R. and John W. Sullivan Foundation Mr. and Mrs. P. Richard Frieder Mr. C. Cresson Wistar Mrs. Honey Friedman William and Sandra Friel Mr. and Mrs. Robert Gamberg Dr. and Mrs. Alfred E. Goldman PRESIDENT’S SOCIETY DIRECTORS $2,500+ Eden Graber and Rick Tilton Greater Philadelphia Chamber of Commerce Mr. Robert Angevine Dr. Jennifer Gross and Mr. Eli Gross Ms. Mary E. Bak Mr. and Mrs. Patrick E. Hanraty Cozen O’Connor John G. Harkins, Jr. Kenneth J. Davis, Esq. and Susan Charleston Dr. and Mrs. Scott H. Herbert Dolfinger-McMahon Foundation Mr. L. Harvey Hewitt Father’s Day Mother’s Day Council, Inc. Hillel of Greater Philadelphia Firstrust Bank The Honorable and Mrs. Harris N. Hollin Mr. and Mrs. Bruce A. Gillespie Holt Logistics Corp. Helen F. Graham Cancer Center at Christiana Care Howson & Howson LLP Mr. Joseph F. Grusemeyer Carol and Lawrence Huff Mr. and Mrs. Laurence Holbert Ms. Kelly Irwin Mr. and Mrs. Ira M. Ingerman Mr. and Mrs. Stephen J. Izzi Mr. Leroy E. Kean Mr. and Mrs. Stephen R. Jacobs Mr. and Mrs. Tom Kirchhoff Ms. Janet Kardon

2014 ANNUAL REPORT 31 Mr. and Mrs. James P. Kimmel, Jr. Mr. and Mrs. William Kirchhoff Mr. and Mrs. Leonard M. Klehr BENEFACTORS $500+ Mr. Zachary Klehr Mrs. Donna Aird Mr. and Mrs. Harvey S. Kronfeld Mr. and Mrs. Robert M. Alper Polly and Bob Lam Mr. Thomas J. Baldoni Ms. Elaine Levitt Mr. Peter A. Benoliel and Ms. Willo Carey Mr. and Mrs. Robert P. Levy Luther Weldon Brady, M.D. Mr. James C. Li and Mrs. Audrey Yeung Dr. Margo Ann Brinton Mr. and Mrs. James J. Lynch Mr. Carl Buchholz Mr. and Mrs. Larry Magid Mr. and Mrs. Cummins Catherwood, Jr. Mr. Drew Moss Mr. and Mrs. Robert Hacker Clapham, Sr. Maureen Murphy, Ph.D. Mr. Michael Connelly Mr. and Mrs. Charles Murray Mr. and Mrs. Samuel E. Dennis Mr. and Mrs. Ronald J. Naples Dr. and Mrs. John DiIulio Mr. and Mrs. Henry N. Nassau Mr. and Mrs. Howard Fischer Dr. and Mrs. Paul Allan Offit Mr. John W. Fowler, Jr. Mr. and Mrs. Dean C. Pappas Mr. and Mrs. Andrew A. Goldman Penn Center for AIDS Research Mrs. Barbara Gomes Dr. Richard Pestell Mr. and Mrs. Robert Goodman Mr. Edward A. Piscopo Gospel Temple Baptist Church Pottsville Broadcasting Co., Inc. Dr. and Mrs. Allan Greenspan Vincent E. Price, Ph.D. Mr. Joshua S. Gross Alan and Louise Reed Mr. Lawrence Hollin Mrs. Claire Reichlin Dr. F. Kay Huebner Mr. and Mrs. Stanley Reichlin Barbara B. Knowles, Ph.D. Mr. William J. Reulbach and Ms. Lisa Bierly Dr. and Mrs. David Koch Dr. and Mrs. Donald Vail Rhoads Mr. and Mrs. Brent Kornman Mr. Samuel Vail Rhoads Mrs. Lillian S. Kosloff Mr. Jay Rosenbluth Mr. and Mrs. Mark Lenet Dr. Harry Rosenthal in Memory of the Mr. Edward W. Levin Rosenthal-Moellerich-Voehl Families Mrs. Judith Lieb Mr. and Mrs. Marvin J. Rounick Mr. and Mrs. Sheldon J. Liss Mr. and Mrs. Edward J. Ryan Alexa Lustig Saul Ewing LLP Maureen and James McCabe Karen and George Sauter Mrs. Joan Miller Mr. James R. Schaeffer and Ms. Nicole Dresnin Mr. and Mrs. Robert A. Miller Mr. and Mrs. Richard Seitchik Leah Reinhard Franz W. Sichel Foundation Dr. and Mrs. Kenneth Scott Resnik Mr. and Mrs. Howard A. Silverman Mr. and Mrs. Richard M. Rosenbleeth Mr. and Mrs. Morton H. Simkins Dr. Caroline S. Rhoads Mr. and Mrs. Edward Tawil Nancy H. Rhoads and Adam L. Glick Tim Turnham Ph.D. Lucy B. Rorke-Adams, M.D. University City Science Center Dr. and Mrs. Louis F. Rose University of the Sciences in Philadelphia Mr. and Mrs. Louis E. Rousso David U’Prichard Ph.D. Mr. Michael Roynan Mr. and Mrs. Charles H. Vetterlein Siegelvision Donna and Lester Weinraub Mr. and Mrs. Charles H. Silverman Mr. and Mrs. Raymond H. Welsh Ms. Cathi Snyder Wilf Family Foundations Mr. William Stamps Miss Caroline P. Wistar Ellen R. Stubbs, M.D. Mr. Gil Wistar T & N Van Services Mr. James B. Wistar Monica and Thomas Teesdale The Worsham Family Foundation Dr. Lynne Tobin Mr. and Mrs. Gilbert Tucker Mrs. Kevin Tucker Mr. Joseph Trainor Mr. David Urbach WHYY, Inc. Dr. and Mrs. Michael Widlitz Mr. and Mrs. Bernard Zolot

* deceased

Each of our donors is important to us and we make every effort to follow the donor’s preferences when compiling the annual report list. Gifts mentioned exclude in-kind donations and multiple-year pledges. Please notify us of any omissions or errors so we can correct our records. Please contact the development office at 215.898.3930 or email [email protected].

32 THE WISTAR INSTITUTE THE PEW CHARITABLE TRUSTS

UNPARALLELED CONTRIBUTIONS The Pew Charitable Trusts has been a longtime supporter of The Wistar Institute. Since 1969, Pew has generously awarded 27 grants, totaling more than $12 million. Pew awards have supported a variety of purposes including building renovations, specialized equipment purchases and focused research assistance. Since 1992, support from Pew has enabled Wistar to recruit 23 researchers and to continue enlisting upper echelon scientific investigators conducting world- class cancer research.

In addition, several Wistar scientists have been awarded individual grants through the Pew Scholars Program in the Biomedical Sciences. Every year, early-career researchers from across the nation compete for 22 awards, each providing a total of $240,000 in funding over four years, to develop their scientific projects.

The Pew Charitable Trusts is a nonprofit organization that applies a rigorous, analytical approach to improve public policy, inform the public, and invigorate civic life. In Philadelphia, Pew encourages a thriving arts and cultural community; supports the health and welfare of the region’s most vulnerable populations; informs discussion on important issues facing the city; and, more broadly, strengthens the area’s appeal to residents and visitors alike.

Previously supported Wistar scientists: Maureen Murphy, Ph.D., Rugang Zhang, Ph.D., and Dmitry Gabrilovich, M.D., Ph.D.

2014 ANNUAL REPORT 33 HERITAGE SOCIETY

The Wistar Heritage Society recognizes the foresight and generosity of individuals who elect to perpetuate their support of biomedical research by including the Institute in their wills or estate plans. The Wistar Institute appreciatively recognizes these members as of December 31, 2014:

Francis X. Bresnan Ira Brind June H. Chern Peter E. Corrado Harold M. Davis Joan M. Farkas Dr. and Mrs. Jerome I. Flicker Robert A. Fox Bruce A. Gillespie Stan and Arlene Ginsburg Family Foundation Dr. and Mrs. Alfred E. Goldman Mr. and Mrs. Bruce A. Goodman Joseph F. Grusemeyer Dorothee M. Herlyn, D.V.M., D. Sc. Meenhard Herlyn, D.V.M., D. Sc. The Honorable Harris N. Hollin Mrs. Constance Jordan Miss Rivka Kaestner Russel E. Kaufman, M.D. Herbert Kean, M.D. Ms. Deborah Komins Evelyn S. Kritchevsky Mr.* and Mrs. Thomas F. Lafferty Howard L. Lipschutz Glorita P. Maida Kurtis L. Meyer Paula R. Meyer E. K. Pomerantz Miller Sandya Narayanswami, Ph.D. Ms. Carol B. O’Neill Ms. Rosetta Perno Elizabeth A. Pesce and Timothey P. Pesce Seymour S. Preston III and Jean E.H. Preston Lt. Col. Carolyn Reinbold The Edward and Elsa Rhoads Trust Dr. Harry Rosenthal in Memory of the Rosenthal- Moellerich-Voehl Families Emily Brown Shields Ed Sickles Family The Wistar Postdoctoral Program James B. Wistar supports the next generation of Wistar Joan H. Wister scientists with programs tailored to enhance their training. At any one time, there are between 75-100 postdoctoral fellows and 45 graduate students at The Wistar Institute, and outside the rigors of work, postdocs make time for fun. On Aug. 8, 2014, the Annual Ice Cream Social took place. A 50:50 raffle raised funds for educational programs and attendees hung around until each and every last scoop of gelato was finished.

34 THE WISTAR INSTITUTE WISTAR FAMILY GIFTS

The Wistar Institute was founded in 1892 through Martha and I. Wistar Morris III generous gifts from Isaac Jones Wistar, a prominent Mrs. Elizabeth Haines Morris Philadelphia lawyer and former Civil War Brigadier Anne Rhoads and Noureddine Melikechi Dr. Caroline S. Rhoads General, in honor of his great uncle, Caspar Wistar, Dr. and Mrs. Donald Vail Rhoads M.D., a physician and the author of the first American The Edward and Elsa Rhoads Trust textbook on anatomy. Isaac Wistar’s descendants, as Nancy H. Rhoads and Adam L. Glick well as those of Dr. Caspar Wistar, continue to support Mr. Samuel Vail Rhoads the Institute to this day. The Wistar Institute gratefully Inés and William Rhoads acknowledges the following family members who Gloria Marin Darthea Sharples, Ph.D. made contributions in 2014. Mr. C. Cresson Wistar Mr. and Mrs. Caleb C. Wistar IV Miss Caroline P. Wistar Ms. Mary Rhoads Alexander Mr. Gil Wistar Marion and Frederic Ballard Mr. James B. Wistar Charles J. Bauernschmidt, Esquire Mrs. Laura J. Belman Mr. Nicholas W. Brown Sandra and Robert Clapham Mrs. Barbara Lea Couphos Mrs. Eleanor M. Cox Beth and J. Brooke Gardiner Brigadier General Isaac Jones Wistar’s sword ushered Marin Shawn Haynes in a new era of Wistar Science at the opening Ms. Elizabeth Wistar Little ceremony of the Robert and Penny Fox Tower on Mr. William M. MacDonald Sept. 12, 2014. Surrounded by Rhoads family Mrs. Pierre E. Martin members and James Wistar, Dr. Russel Kaufman cut the ribbon for the official opening of the Robert and Penny Fox Tower before a crowd of hundreds.

2014 ANNUAL REPORT 35 THE WISTAR INSTITUTE BOARD OF TRUSTEES

Ira Brind Samuel V. Rhoads President Executive Vice President OFFICERS Brind Investments, Inc. Philadelphia Industrial Development Corporation CHAIR Ronald L. Caplan Helen P. Pudlin, Esq. President Robert H. Rock Retired Executive Vice President Philadelphia Management Corp. President and General Counsel MLR Holdings, LLC The PNC Financial Services Group, Inc. Brian H. Dovey General Partner Gerald B. Rorer VICE CHAIR Domain Associates Richard M. Horowitz Adele K. Schaeffer Daniel K. Fitzpatrick, C.F.A. President Paul J. Schmitt President and CEO R.A.F. Industries, Inc. Managing Director Citizens Bank of PA/NJ/DE/NY SECRETARY Novitas Capital Robert A. Fox Maida Milone Milton S. (Tony) Schneider Chairman and CEO Vice President of Strategic Planning Principal & Founder R.A.F. Industries, Inc. and Business Development, Devereux The Glenville Group, Inc. L. Patrick Gage, Ph.D. TREASURER William A. Slaughter, Esq. Founder & President Alan Stiles Partner enGage Biotech Consulting Chief Operating Officer Ballard Spahr LLP The Wistar Institute Joseph A. Goldblum Judith E. Soltz, Esq. President G-II Equity Investors, Inc. David V. Wachs Mark L. Greenberg, Ph.D. Daniel H. Wheeler Provost President MEMBERS Senior Vice President for Pea Vine Properties Academic Affairs Edward Ziff, Ph.D. Elizabeth McKee Anderson Drexel University Professor, Department of Biochemistry Worldwide Vice President NYU School of Medicine Vaccines, Global Strategic Marketing Herbert Kean, M.D. Johnson & Johnson Perry A. Lerner* Van Billet Chairman & CEO Crown Global Insurance Group, LLC Robert S. Blank Partner Susan S. McDonald, Ph.D. EMERITUS BOARD Whitcom Partners President & CEO NAXION Douglas S. Briggs MEMBERS Abraham L. Morris Co-CEO Harold M. Davis Sunlogics Chairman, Realen Properties Albert Ominsky, Esq. Peter C. Dougherty, Ph.D. Ominsky & Ominsky, P.C. Chairman, Department of Immunology, Arthur M. Pappas St. Jude Children’s Research Hospital Managing Partner Nobel Laureate in Physiology Pappas Ventures or Medicine (1996) Member, National Academy of Sciences Vincent Price, Ph.D. Provost The Honorable Harris N. Hollin Steven H. Chaffee Professor of Faye Olivieri Kozich Communication, Annenberg School for Communication Seymour S. Preston, III University of Pennsylvania The Millrace Group Doris Taxin

* = new in 2014

36 THE WISTAR INSTITUTE THE WISTAR INSTITUTE STAFF AND ADMINISTRATION

Jo-Ann Mendel, M.B.A. Luis J. Montaner, D.V.M., D.Phil. Director, Human Resources Associate Director, Shared Resources STAFF AND Herbert Kean, M.D., Family Professor Marianne O’Neill ADMINISTRATION Director, Research Financial Nicholas J. Petrelli, M.D. Administration Associate Director, Translational Research, Helen F. Graham Cancer Russel E. Kaufman* Raymond Preis Center & Research Institute President and CEO Director, Information Systems Marianne O’Neill Dario C. Altieri, M.D.* Stephen Tustin, C.P.A. Associate Director, Cancer Center Director, The Wistar Institute Director, Finance and Controller Support Grant Finances Cancer Center William H. Wunner, Ph.D. Lisa Sideras Executive Vice President Professor Associate Director, Cancer Chief Scientific Officer Director, Academic Affairs Center Administration Robert and Penny Fox Director of Outreach Education and Distinguished Professor Technology Training Mark Drinker Alan Stiles General Manager, Shared Chief Operating Officer Resources Operations Joseph Trainor Chief Financial Officer Andrew Peabody CANCER CENTER Chief Information Officer ADMINISTRATION CANCER CENTER Elizabeth B. O’Brien, Esq. Vice President, Legal and Dario C. Altieri, M.D. RESEARCH PROGRAMS External Affairs Director Eden Graber 1 Robert and Penny Fox GENE EXPRESSION Vice President, Development Distinguished Professor AND REGULATION and Marketing Frank J. Rauscher, III, Ph.D. Professors Heather A. Steinman, Ph.D., M.B.A. Deputy Director Paul Lieberman, Ph.D. Vice President, Business Development Paul Lieberman, Ph.D. Program Leader Executive Director, Technology Transfer Program Leader, Gene Hilary Koprowski, M.D., Maureen Murphy, Ph.D. Expression and Regulation Endowed Professor Associate Vice President, Hilary Koprowski, M.D., Kazuko Nishikura, Ph.D. Faculty Affairs Endowed Professor Frank J. Rauscher, III, Ph.D. 1 Maureen Murphy, Ph.D. Josie Burri Associate Professors Director, Major Gifts Program Leader, Molecular and Cellular Oncogenesis Ken-ichi Noma, Ph.D. 1 Greg Lester Associate Director, Education Emmanuel Skordalakes, Ph.D. Acting Director, Communications and Career Development Rugang Zhang, Ph.D. Elyse Hoffmann David W. Speicher, Ph.D. Senior Staff Scientists Director, Donor Relations Program Co-Leader, Molecular Zhong Deng, Ph.D. and Special Events and Cellular Oncogenesis Hongzhuang Peng, Ph.D. Van Cherington, Ph.D. Caspar Wistar Professor in Staff Scientists Director, Science Administration Computational and Systems Biology Troy E. Messick, Ph.D. April Miller José Conejo-Garcia, M.D., Ph.D. Masayuki Sakurai, Ph.D. Director, Library Services Program Leader, Tumor Curator of The Wistar Museum Microenvironment and Metastasis Associate Staff Scientists Jayaraju Dheekollu, Ph.D. Collections Dmitry I. Gabrilovich, M.D., Ph.D. Jayashree Karar, Ph.D. Program Leader, Translational James E. Zaleski Fan Lai, Ph.D. Tumor Immunology Director, Facilities Fang Lu, Ph.D. ¹ Christopher M. Davis Professor Osamu Iwasaki, Ph.D.

2014 ANNUAL REPORT 37 MOLECULAR AND Senior Staff Scientists CELLULAR ONCOGENESIS Livio Azzoni, M.D., Ph.D. Kiranmai Gumireddy, Ph.D. Professors Michael P. O’Connell, Ph.D. ¹ Maureen Murphy, Ph.D. Emmanouil Papasavvas, Ph.D. Program Leader Costin Tomescu, Ph.D.

David W. Speicher, Ph.D. Staff Scientists Program Co-Leader Adina-Monica Vultur, Ph.D. Caspar Wistar Professor in Systems Amaya Wolf, Ph.D. ¹ and Computational Biology Ellen Heber-Katz, Ph.D. ¹ Associate Staff Scientists Melanie R. Rutkowski, Ph.D. Meenhard Herlyn, D.V.M., D.Sc. Tom L. Stephen, Ph.D. Caspar Wistar Professor in Thomas C. Condamine, Ph.D. Melanoma Research Batool Shannan, Ph.D. Louise C. Showe, Ph.D. Haikun Wang, Ph.D. ¹

Associate Professors Qin Liu, M.D., Ph.D. TRANSLATIONAL TUMOR Harold Riethman, Ph.D. IMMUNOLOGY

Assistant Professors Professors Susan Janicki, Ph.D. Dmitry I. Gabrilovich, M.D., Ph.D. Jessie Villanueva, Ph.D. Program Leader Christopher M. Davis Professor Senior Staff Scientists Andrew Caton, Ph.D. Michael K. Showe, Ph.D. ¹ Jan Erikson, Ph.D. Tao Wang, Ph.D. ¹ Luis J. Montaner, D.V.M., D.Phil. Herbert Kean, M.D., Family Professor Staff Scientists Noor B. Dawany, Ph.D. ¹ Associate Professor Jagadish C. Ghosh, Ph.D. Chih-Chi Hu, Ph.D. Sharmistha Pal, Ph.D. ¹ Assistant Professor Associate Staff Scientists Scott E. Hensley, Ph.D. Young Chan Chae, Ph.D. Michele Tavecchio, Ph.D. CANCER CENTER SHARED RESOURCES TUMOR MICROENVIRONMENT Shared Resources AND METASTASIS Scientific Directors Andrew Caton, Ph.D. Professors Susan Janicki, Ph.D. Dario C. Altieri, M.D. Paul Lieberman, Ph.D. Robert and Penny Fox Luis J. Montaner, D.V.M., D. Phil. Distinguished Professor Louise C. Showe, Ph.D. David W. Speicher, Ph.D. Associate Professors Dr. Meenhard Herlyn’s lab José Conejo-Garcia, M.D., Ph.D. Shared Resources pioneered the use of three- Program Leader Managing Directors dimensional “artificial skin” to Hui Hu, Ph.D. ¹ Livio Azzoni, M.D., Ph.D. study melanoma cells and how Qihong Huang, M.D., Ph.D. Celia Chang, Ph.D. they interact amid normal cells. Denise DiFrancesco, A.S., The ability to create artificial skin Assistant Professors R.L.A.T., I.L.A.M., C.M.A.R. gives Herlyn’s lab unique insight Yulia Nefedova, M.D., Ph.D. Jeffrey S. Faust, B.S., M.B.A. into understanding the way Ashani Weeraratna, Ph.D. James Hayden, B.A., R.B.P., F.B.C.A. melanoma cells work, and also Robert Hills, Ph.D. serves as a proving ground for Research Assistant Professors Andrei Kossenkov, Ph.D. future therapeutics. Mizuho Kalabis, M.D., Ph.D. David Schultz, Ph.D. ¹ Clemens Krepler, Ph.D. Hsin-Yao Tang, Ph.D. Rajasekharan Somasundaram, Ph.D.

38 THE WISTAR INSTITUTE Nicholas J. Petrelli, M.D. 4 Helen F. Graham Cancer Center VACCINE CENTER ROBERT A. FOX & Research Institute STRUCTURAL George G. Prendergast, Ph.D. 4 Hildegund C.J. Ertl, M.D. Lankenau Institute for Medical Research Director, Caspar Wistar Professor BIOLOGY CENTER in Vaccine Research Ulrich Rodeck, M.D. Thomas Jefferson University Assistant Professor Member Emmanuel Skordalakes, Ph.D. Charles E. Rupprecht, V.M.D., Ph.D. Scott E. Hensley, Ph.D. Global Alliance for Rabies Control Senior Staff Scientists Thomas D. Stamato, Ph.D. 4 Zhi Quan Xiang, M.D. Lankenau Institute for Medical Research Xiang Yang Zhou, M.D., Ph.D. Adjunct and Affiliate PROFESSORS EMERITI Associate Professors Michael R. Betts, Ph.D. 4 Clayton Buck, Ph.D. University of Pennsylvania Roger M. Burnett, Ph.D. 4 MELANOMA Walter Gerhard, M.D. Horace M. Delisser, M.D. Dorothee Herlyn, D.V.M., D.Sc. University of Pennsylvania RESEARCH CENTER Elliot Levine, Ph.D. K. Ann Jeglum, V.M.D. Stanley A. Plotkin, M.D. Veterinary Oncology Services Meenhard Herlyn, D.V.M., D.Sc. Robert Roosa, Ph.D. and Research Center Director Leonard Warren, M.D., Ph.D. Zofia Wroblewska, M.D. Steven B. McMahon, Ph.D. Thomas Jefferson University Members Russel E. Kaufman, M.D. Zhi Wei, Ph.D. 4 Jessie Villanueva, Ph.D. ADJUNCT AND New Jersey Institute of Technology Ashani Weeraratna, Ph.D. AFFILIATE FACULTY Xiaowei Xu, M.D., Ph.D. 4 Adjunct Professors University of Pennsylvania Stephen M. Albelda, M.D. 4 University of Pennsylvania Adjunct and Affiliate Assistant Professors CENTER FOR SYSTEMS Richard Assoian, Ph.D. 4 Ravi Amaravadi, M.D. 4 University of Pennsylvania University of Pennsylvania AND COMPUTATIONAL Shelley Berger, Ph.D. Devraj Basu, M.D., Ph.D. 4 BIOLOGY University of Pennsylvania University of Pennsylvania Gerd Blobel, M.D., Ph.D. 4 David Garlick, Ph.D. 4 David W. Speicher, Ph.D. Children’s Hospital of Philadelphia Histo-Scientific Research Laboratories Director Timothy Block, Ph.D. F. Bradley Johnson, M.D., Ph.D. 4 Louise C. Showe, Ph.D. Drexel University University of Pennsylvania Associate Director and Anthony Capobianco, Ph.D. Alexander Roesch, M.D. Director of Genomics University of Miami The Saarland University Hospital Dennis E. Discher, Ph.D. 4 Fiona Simpkins, M.D. University of Pennsylvania University of Pennsylvania Cesare Furlanello, Ph.D. Julia C. Tchou, M.D., Ph.D. 4 ALBERT R. TAXIN BRAIN Fondazione Bruno Kessler University of Pennsylvania Phyllis A. Gimotty, Ph.D. 4 TUMOR RESEARCH CENTER University of Pennsylvania Mark I. Greene, M.D., Ph.D., F.R.C.P. 4 Susan Janicki, Ph.D. University of Pennsylvania LEGEND Thanos D. Halazonetis, D.D.S., Ph.D. 4 1 Departed in 2014 University of Geneva 2 Secondary appointment 3 Deceased 2014 Katherine A. High, M.D. 4 Affiliate member of the Cancer Center CENTER FOR CHEMICAL Children’s Hospital of Philadelphia * On March 2, 2015, Russel E. Kaufman, M.D., stepped down as president and CEO 4 BIOLOGY AND Ronen Marmorstein, Ph.D. to become president emeritus of The Wistar University of Pennsylvania Institute. Dario C. Altieri, M.D., succeeded TRANSLATIONAL MEDICINE Reynold A. Pannettieri, Jr., M.D. 4 Kaufman as president and CEO of The Wistar Institute and will continue to serve as University of Pennsylvania director of Wistar’s Cancer Center. Paul Lieberman, Ph.D. Director

2014 ANNUAL REPORT 39 FINANCIALS

TOTAL NUMBER NUMBER OF COUNTRIES* NUMBER OF OF EMPLOYEES OF ORIGIN REPRESENTED LABORATORIES 359 31 31

NUMBER OF NUMBER OF NUMBER OF POST-DOCTORAL FELLOWS PRE-DOCTORAL FELLOWS VISITING SCIENTISTS 45 33 10

*Albania, Argentina, Austria, Brazil, Bulgaria, Canada, China, Ecuador, France, Germany, Greece, Hungary, India, Indonesia, Italy, Jordan, Japan, Korea, Luxembourg, Peru, Poland, Russia, Singapore, Spain, Sri Lanka, Syria, Taiwan, United Arab Emirates, United Kingdom, United States, Vietnam

PATENTS ISSUED SHARED RESOURCES U.S. Patent No. 8,669,243 Animal Facility Steroid-Derived Cyclopamine Bioinformatics Facility Analogs and Methods for BSL-3 Facility Using the Same in the Prevention Flow Cytometry Facility or Treatment of Cancer Genomics Facility Filed: 06/15/2011 Histotechnology Facility Issued: 03/11/2014 Imaging Facility Inventors: Nadia Dahmane Molecular Screening Facility Jeffrey D. Winkler Phlebotomy Facility Protein Expression Facility U.S. Patent No. 8,759,367 Proteomics Facility Compounds and Methods Research Supply Center for the Prevention and Translational Research Treatment of Cancer Management Facility Filed: 10/04/2011 Vector Core Issued: 06/24/2014 Inventors: Nadia Dahmane Jeffrey D. Winkler Andre Isaacs

40 THE WISTAR INSTITUTE SOURCES OF FUNDS

● Federal grant funding $ 32,439,000 51%

● Foundation and other private funding 4,773,000 8%

● State funding 606,000 1%

● Corporate-sponsored research 1,401,000 2%

● Unrestricted contributions 558,000 1%

● Capital campaign contributions 3,125,000 5%

● Technology transfer 18,209,000 28%

● Investment and other 2,849,000 4%

$ 63,960,000 100%

SOURCES OF FUNDS

2014 ANNUAL REPORT 41 FINANCIALS

USES OF FUNDS

● Direct research $ 32,565,000 52%

● General and administrative 11,055,000 17%

● Operation and maintenance of plant 7,655,000 12%

● Depreciation/disposals of capital assets 5,550,000 9%

● Interest expense 898,000 1%

● Pension and interest rate swap losses 5,527,000 9%

$ 63,250,000 100%

Change in net assets $ 710,000

USES OF FUNDS

42 THE WISTAR INSTITUTE Zachary Klehr Paul N. Urick, R.Ph. Executive Vice President, Franklin Senior Vice President of Pharmaceutical LEADERSHIP COUNCIL Square Capital Partners Operations, Cigna Corporation James C. Li Dr. Aubrey Watkins III CO-CHAIRS Vice President, Commercial Lending, Director, Business Development Max Berger First Federal of Bucks County & Licensing (Transactions Manager), Merck President, MBA Equities Michelle Mayer Donna F. Weinraub, CPCU, ARM Account Manager, Managed Bryan Weingarten Senior Vice President, Corporate Risk Healthcare Services, Lilly USA Chief Executive Officer, WP Realty Solutions, Willis of Pennsylvania Kevin P. McDermott, CFP®, RFC Jeremiah J. White, Jr. Founding Partner, The President and CEO, Jeremiah MEMBERS Philadelphia Group J. White & Associates Mary E. Bak Jennifer Mendel James Wistar Partner, Howson & Howson LLP Principal Partner, Blue Fox Advisors LLC Chairman, President and CEO, Everite Door Company Marla Conley, Esq. Patrick M. Oates, Ph.D. Nonprofit Organizations Practice Group Vice President, Science Education, Craig F. Zappetti Co-Chair, Schnader Attorneys at Law Universal Companies Partner, Saul Ewing LLP Kenneth J. Davis, Esq. Elizabeth A. Pesce Partner, Morgan Lewis CFO, Beco Kitchens and Bathrooms Elizabeth Gabor Edward Piscopo Real Estate Manager, IKEA Group Regional Director of Economic THE AMBASSADORS OF Keith Gaspard Development, PECO, an Partner - Life Sciences, Exelon Company THE WISTAR INSTITUTE Odgers Berndtson Ellen Riccobene, M.D. Bruce A. Gillespie Medical Director, Lynsie Solomon (chair) Retired Commercial Banker Independence Blue Cross Katie Adams Merle Gilmore Eric Rugart Founder and Principal, Merle Co-Founder, ZSX Medical Allison Becker Gilmore & Associates Edward J. Ryan Ian Michael Crumm Joseph F. Grusemeyer Executive Advisory Board, Wells Fargo Bank Peter Dilsheimer Scott H. Herbert, M.D. Ken Greenberg Chief, Radiation Oncology, Jim Schaeffer The Rosenfeld Cancer Center, President and Founder, Gabriela Guaracao Abington Memorial Hospital Ruby’s of Pennsylvania Elizabeth Lampen Kim Liza Herzog Evan Solomon Marc Kim, M.D. Director of Research, CEO, EFS Networks Inc. Philadelphia Education Fund Lynsie Solomon Alexa Lustig Larry Hollin Department of Public Property, Michael Magnatta City of Philadelphia Partner, Arch Street Advisors Julia Sherwood Murphy Alex Stanbach Rick Horowitz Katie Pellecchia President, RAF Industries, Inc. Project Manager, UBC: An Express Scripts Company Jenny Perkins Carol G. Huff President, Real Estate Greg Stanbach Leah Reinhard Senior Vice President, RBS Citizens Investment Strategies, Inc. Cory Siegfried James D. Troyer, CFA Sharon Tobin Kestenbaum Garrett Getlin Snider President, Bala Properties Group, Inc. Principal and Portfolio Manager, The Vanguard Group 3601 SPRUCE STREET PHILADELPHIA, PA 19104-4265 215.898.3700

The Wistar Institute’s 2014 Annual Report was produced by the Office of Development and Marketing

ELYSE HOFFMANN Director of Donor Relations and Special Events

DARIEN SUTTON Senior Media Relations Associate

BEN LEACH Digital Content Specialist

JESSICA MARTINEZ Administrative Coordinator, Development and Marketing

WRITERS: Darien Sutton, Ben Leach, Laura Feragen, Allyson Groff

DESIGN: Anne Marie Kane, Imogen Design

COVER DESIGN: Cindy Jensen Graphic Design

PHOTOGRAPHY: Daniel Burke Photography, Tommy Leonardi, Darien Sutton

The Wistar Institute is an equal opportunity/affirmative action employer. It is the policy of The Wistar Institute to provide equal employment opportunities to all individuals regardless of race, color, creed, religion, national origin, ancestry, sex, age, veteran status, disability, sexual orientation, gender identity, or on the basis of genetic information, or any other characteristic protected by federal, state, or local law, with respect to all terms and conditions of employment.